Medicaloid

Pharma

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%

Medicaloid
Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail...

After probing AstraZeneca’s COVID-19 vaccine safety, European regulators add warning over rare blood clots

Medicaloid
Europe’s drug regulator has been probing cases of rare blood clots in AstraZeneca COVID-19 vaccine recipients since mid-March—and now it has confirmed a possible link. The agency...

Valneva reports positive Phase 1/2 data for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001

Medicaloid
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced...